Detalles de la búsqueda
1.
Weight loss and outcomes in subjects with progressive pulmonary fibrosis: data from the INBUILD trial.
Respir Res
; 24(1): 71, 2023 Mar 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-36894966
2.
Dyspnoea and cough in patients with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial.
Rheumatology (Oxford)
; 61(11): 4397-4408, 2022 11 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35150246
3.
Dural Arteriovenous Fistulae After Cerebral Venous Thrombosis.
Stroke
; 51(11): 3344-3347, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32972315
4.
Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial.
Am Heart J
; 212: 13-22, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30928824
5.
Dabigatran for Treatment and Secondary Prevention of Venous Thromboembolism in Pediatric Congenital Heart Disease.
J Am Heart Assoc
; 13(4): e028957, 2024 Feb 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38348778
6.
Risk of Malnutrition in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease Treated With Nintedanib in the Randomized, Placebo-Controlled SENSCIS Trial.
Arthritis Care Res (Hoboken)
; 75(12): 2501-2507, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37357024
7.
Impact of lung function decline on time to hospitalisation events in systemic sclerosis-associated interstitial lung disease (SSc-ILD): a joint model analysis.
Arthritis Res Ther
; 24(1): 19, 2022 01 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35012623
8.
Nintedanib in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score.
Arthritis Rheumatol
; 74(3): 518-526, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34514739
9.
Recanalization after cerebral venous thrombosis. A randomized controlled trial of the safety and efficacy of dabigatran etexilate versus dose-adjusted warfarin in patients with cerebral venous and dural sinus thrombosis.
Int J Stroke
; 17(2): 189-197, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33724104
10.
Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCI.
Eur Heart J Cardiovasc Pharmacother
; 8(3): 216-226, 2022 05 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33258897
11.
The effect of sex on the efficacy and safety of dual antithrombotic therapy with dabigatran versus triple therapy with warfarin after PCI in patients with atrial fibrillation (a RE-DUAL PCI subgroup analysis and comparison to other dual antithrombotic therapy trials).
Clin Cardiol
; 44(7): 1002-1010, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-34042199
12.
Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial.
JACC Cardiovasc Interv
; 14(7): 768-780, 2021 04 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33826497
13.
Dual antithrombotic therapy with dabigatran in patients with atrial fibrillation after percutaneous coronary intervention for ST-segment elevation myocardial infarction: a post hoc analysis of the randomised RE-DUAL PCI trial.
EuroIntervention
; 17(6): 474-480, 2021 Aug 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-33164896
14.
Comparison of the Effect of Age (< 75 Versus ≥ 75) on the Efficacy and Safety of Dual Therapy (Dabigatranâ¯+â¯Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarinâ¯+â¯Aspirinâ¯+â¯Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the RE-DUAL PCI Trial).
Am J Cardiol
; 125(5): 735-743, 2020 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31924322
15.
Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention: A Subgroup Analysis From the REDUAL PCI Trial.
Circ Cardiovasc Interv
; 13(4): e008349, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32252548
16.
Dabigatran Dual Therapy vs Warfarin Triple Therapy Post-Percutaneous Coronary Intervention in Patients with Atrial Fibrillation With/Without a Proton Pump Inhibitor: A Pre-Specified Analysis of the RE-DUAL PCI Trial.
Drugs
; 80(10): 995-1005, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-32562206
17.
Comparison of Dabigatran Plus a P2Y12 Inhibitor With Warfarin-Based Triple Therapy Across Body Mass Index in RE-DUAL PCI.
Am J Med
; 133(11): 1302-1312, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32389658
18.
Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post-PCI in Patients With Atrial Fibrillation and Diabetes.
JACC Cardiovasc Interv
; 12(23): 2346-2355, 2019 12 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31806216
19.
Reply: Our Perspective on Anticoagulation Therapy Post-PCI in Atrial Fibrillation Patients With Diabetes.
JACC Cardiovasc Interv
; 13(5): 658-659, 2020 03 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32139229
20.
Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post PCI in Patients With Atrial Fibrillation.
J Am Coll Cardiol
; 75(2): 238-240, 2020 01 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-31948654